October 1, 2021

Positive clinical trial results for Merck’s experimental anti-viral COVID-19 pill is shaking the healthcare sector and sending the drugmaker’s stock price soaring. Our Kevin Gade told Reuter’s News the announcement was a windfall for Merck, which had seen its shares fall after discontinuing its COVID-19 vaccine program.

“Merck has kind of been dead in the water to investors for the past couple of quarters,” said Kevin Gade, portfolio manager with Bahl & Gaynor. “This shows their R&D engine is not dead and they were first … in what could be a multi-billion dollar opportunity.”

Kevin T. Gade, CFA, CFP
Portfolio Manager
kgade@bahl-gaynor.com

Read the full article HERE (a subscription may be required).